ASAS-EULAR Rec for AxSpA 2022 ◦ NSAIDs are first line ◦ b/tsDMARDs when ASDAS >2.1 ◦ Uveitis/IBD ➤TNFi ◦ Psoriasis ➤IL-17i ◦ Review Dx if Rx failure ◦ Switch if active disease confirmed ◦ Taper bDMARDs if sustained remission Jose Scher #ReviewCourse @RheumNow #ACR22 https://t.co/8fGwlZWBDS